Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
xCures
University of California, San Francisco
St. Jude Children's Research Hospital
Second Life Therapeutics
Merus B.V.
Eli Lilly and Company
Eli Lilly and Company
Atara Biotherapeutics
British Columbia Cancer Agency
AstraZeneca
Eisai Inc.
Peking University Cancer Hospital & Institute
Eisai Inc.